USPTO serial 79340798
Serial No. 79340798
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 9, 2024
- Examiner
- SWIFT, GILBERT M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79340798?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David Johnson
David Johnson Workman Nydegger60 E South Temple, Suite 1000Salt Lake City, UT 84111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of pain, viral diseases, namely, coronavirus, herpes, and hepatitis, cancer, lung cancer, pancreatic cancer, haematological cancer, colorectal cancer, breast cancer, bladder cancer, cervical cancer, gynecologic cancer, head and neck cancer, kidney cancer, liver cancer, myeloma, ovarian cancer, prostate cancer, skin cancer, thyroid cancer, uterine cancer, and neurological cancer, mental and physical disorders and conditions, namely, schizophrenia, mental health disorders, eating disorders and addictions, and nicotine addiction, skin conditions, namely, dermatitis, skin pigmentation diseases, psoriasis, and eczema, respiratory infections, eye infections, bacterial and parasitic infections, namely, malaria and tuberculosis, respiratory conditions, anxiety, arthritis, neurological diseases, namely, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, immunologic diseases and disorders, namely Alzheimer's, Parkinson's disease, ulcerative colitis, multiples sclerosis, immuno-oncological diseases, atopic dermatitis, asthma, inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), and chronic obstructive pulmonary diseases (COPD), musculoskeletal diseases, bone diseases, central nervous system (CNS) diseases, peripheral nervous system (PNS) diseases, and cardiovascular diseases and disorders; Medical preparations for the treatment of pain, viral diseases, namely, coronavirus, herpes, and hepatitis, cancer, lung cancer, pancreatic cancer, haematological cancer, colorectal cancer, breast cancer, bladder cancer, cervical cancer, gynecologic cancer, head and neck cancer, kidney cancer, liver cancer, myeloma, ovarian cancer, prostate cancer, skin cancer, thyroid cancer, uterine cancer, and neurological cancer, mental and physical disorders and conditions, namely, schizophrenia, mental health disorders, eating disorders and addictions, and nicotine addiction, skin conditions, namely, dermatitis, skin pigmentation diseases, psoriasis, and eczema, respiratory infections, eye infections, bacterial and parasitic infections, namely, malaria and tuberculosis, respiratory conditions, anxiety, arthritis, neurological diseases, namely, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, immunologic diseases and disorders, namely Alzheimer's, Parkinson's disease, ulcerative colitis, multiples sclerosis, immuno-oncological diseases, atopic dermatitis, asthma, inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), and chronic obstructive pulmonary diseases (COPD), musculoskeletal diseases, bone diseases, central nervous system (CNS) diseases, peripheral nervous system (PNS) diseases, and cardiovascular diseases and disorders; Veterinary preparations for the treatment of pain, viral diseases, namely, paramyxovirus, influenza A virus, coronavirus, herpes, and hepatitis, wounds, cancer, lung cancer, pancreatic cancer, haematological cancer, colorectal cancer, breast cancer, bladder cancer, cervical cancer, gynecologic cancer, head and neck cancer, kidney cancer, liver cancer, myeloma, ovarian cancer, prostate cancer, skin cancer, thyroid cancer, uterine cancer, and neurological cancer, mental and physical disorders and conditions, namely, mental health disorders, musculoskeletal diseases, bone diseases, central nervous system (CNS) diseases, cardiovascular diseases and disorders, skin conditions, namely, dermatitis, skin pigmentation diseases, psoriasis, and eczema, respiratory infections, eye infections, bacterial and parasitic infections, namely, malaria and tuberculosis, respiratory conditions, arthritis, inflammatory diseases, namely, inflammatory bowel diseases, and inflammatory connective tissue diseases, immunologic diseases and disorders, namely Alzheimer's, ulcerative colitis, immuno-oncological diseases, atopic dermatitis, asthma, inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), and chronic obstructive pulmonary diseases (COPD), allergies, and anxiety; veterinary preparations, namely, vaccines for animals, and sanitary substances for medical use for the treatment of autoimmune diseases, autoimmune diseases, specifically psoriasis, arthritis, and Crohn's disease; sanitary preparations for medical purposes; dietetic food adapted for medical or veterinary use, food for babies; dietetic substances in the nature of dietetic food adapted for medical or veterinary use; Dietary supplements for human beings and animals; plasters for medical purposes; materials for dressings, namely, gauze, bandages; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceutical, veterinary and sanitary substances and preparations, namely, antifungals, antivirals, herbicides, antibiotics | ACTIVE | — |
| 009 | Downloadable computer software for analysis and interpretation of biological data using the combination of biology, computer science, information engineering, mathematics and statistics; Downloadable computer software for computer assisted molecule design; Downloadable computer software for chemical and biological research and analysis; Downloadable computer software for pharmaceutical research and development services; Downloadable computer software for diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for scientific research purposes for use in the field of molecular research and to combat disease; downloadable computer software for use in the research and development of pharmaceutical products; downloadable computer software for cell analysis; downloadable computer software for the use in managing scientific projects; downloadable computer software for the design of chemical structures; downloadable computer software for the analysis of biological or chemical activity; downloadable artificial intelligence software for healthcare, pharmaceuticals and diagnostics | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, analysis, testing in the field of research and development of pharmaceutical products and molecule design and services relating thereto; industrial analysis and industrial research services in the field of research and development of pharmaceutical products, molecule design and robotics for lab automation and industrial design services; quality control and authentication services in the field of works of scientific research for others; design and development of computer hardware and software; Bioinformatic services, namely, analysis and interpretation of biological data using the combination of biology, computer science, information engineering, mathematics and statistics for others; computer assisted molecule design; identification of biological targets, networks and pathways; chemical and biological research and analysis; pharmaceutical research and development services; diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for scientific research purposes to combat diseases | ACTIVE | — |
| 044 | Medical diagnostic testing and medical screening services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Exscientia AI Limited
- Other trademarks owned by Exscientia AI Limited
- Other trademarks owned by Exscientia AI Limited
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 25, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 13, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 13, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 13, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 13, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 1, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 7, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 11, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 11, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 9, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 9, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 9, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 12, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 25, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 25, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 24, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 4, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 16, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 15, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 22, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 22, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 27, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 26, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 25, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 4, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 24, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 20, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 19, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |